# Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

> **NCT00655655** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 96 (estimated)

## Conditions studied

- Gastrinoma
- Glucagonoma
- Insulinoma
- Metastatic Gastrointestinal Carcinoid Tumor
- Metastatic Pheochromocytoma
- Pancreatic Polypeptide Tumor
- Recurrent Gastrointestinal Carcinoid Tumor
- Recurrent Islet Cell Carcinoma
- Recurrent Melanoma
- Recurrent Neuroendocrine Carcinoma of the Skin
- Recurrent Non-small Cell Lung Cancer
- Recurrent Pheochromocytoma
- Recurrent Renal Cell Cancer
- Somatostatinoma
- Stage III Neuroendocrine Carcinoma of the Skin
- Stage IV Melanoma
- Stage IV Non-small Cell Lung Cancer
- Stage IV Renal Cell Cancer
- Thyroid Gland Medullary Carcinoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** everolimus
- **DRUG:** vatalanib
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** dynamic contrast-enhanced magnetic resonance imaging
- **PROCEDURE:** ultrasound imaging

## Key facts

- **NCT ID:** NCT00655655
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2009-09-15
- **Final completion:** 2018-01-11
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655655, "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00655655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*